FDA Grants Marketing Clearance to Cepheid’s Xpert Xpress Flu And Xpert Xpress Flu/RSV

Cepheid has received marketing clearance from the FDA for their Xpert Xpress Flu and Xpert Xpress Flu/RSV.

The built-in redundancy results reduce the impact of seasonal genomic drift in flu viruses that has been a problem with molecular tests.

Both tests deliver results in 20 minutes. — Cynthia Jessup